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The prospect of cell-based therapy for kidney disease
remains controversial despite its immense promise. We had
previously shown that transplanting bone marrow and
hematopoietic stem cells could generate renal cells and lead
to the preservation of kidney function in a mouse model for
cystinosis (Ctns/) that develops chronic kidney injury,
4 months post transplantation. Here, we determined the
long-term effects of bone marrow stem cell transplantation
on the kidney disease of Ctns/ mice 7 to 15 months post
transplantation. Transfer of bone marrow stem cells
expressing a functional Ctns gene provided long-term
protection to the kidney. Effective therapy, however,
depended on achieving a relatively high level of donor-
derived blood cell engraftment of Ctns-expressing cells,
which was directly linked to the quantity of these cells within
the kidney. In contrast, kidney preservation was dependent
neither on renal cystine content nor on the age of the mice at
the time of transplant. Most of the bone marrow-derived cells
within the kidney were interstitial and not epithelial,
suggesting that the mechanism involved an indirect
protection of the tubules. Thus, our model may help in
developing strategies to enhance the potential success of
cell-based therapy for kidney injury and in understanding
some of the discrepancies currently existing in the field.
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Chronic kidney disease is the progressive loss of kidney
function over time that can lead to end-stage renal failure
and increased cardiovascular disease and mortality.1–3 This is
a major health challenge, and developing new therapies is an
important objective. A number of publications have raised
the prospect of doing cell-based therapy for kidney injury
and failure. However, though promising, the therapeutic
potential of stem cell transplantation for renal disorders is
still controversial.4–6
Some authors demonstrated that unfractionated bone
marrow cells (BMCs) and hematopoietic stem cells (HSCs)
could generate tubular cells and improve renal function.7,8
Following a systemic injection of human HSCs 24 h post
injury in immunodeficient mice, Li et al.9 showed selective
recruitment and localization of bone marrow-derived cells to
the kidney vasculature, resulting in the improvement of
the structural and functional recovery as well as the increased
survival. Kalluri and colleagues10,11 showed that BMC trans-
plantation led to the formation of bone marrow-derived
podocytes and mesangial cells in a mouse model for the
hereditary nephropathy of Alport’s syndrome.
On the other hand, some authors deny the possibility that
renal cells can be derived from transplanted BMCs. One
study concluded that intrarenal stem cells but not bone
marrow-derived cells are responsible for the regeneration of
kidney tissue after ischemic injury. Thus, injection of BMCs
does not make any significant contribution to functional or
structural recovery.12 Others showed that bone marrow-
derived cells within the kidney after injury were mostly cells
of lymphoid lineage.13,14 Stokman et al.15 showed that renal
failure after ischemia is improved by HSC mobilization using
cytokines. However, in this model, the cytokines also altered
the underlying inflammatory processes triggered by kidney
injury, and there was no evidence of involvement of the
mobilized HSCs.15 Similarly, they showed that renal fibrosis
was not improved by HSCs mobilized by stem cell factor and
granulocyte-colony stimulating factor treatment after acute
renal injury in mice.16
Given these controversies, it is important to develop new
models for studying strategies to enhance the potential of
success of cell-based therapy for kidney injury and in particular
for chronic kidney injury. The mouse model for cystinosis,
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Ctns/ mice, is an excellent model for chronic kidney disease.
C57BL/6 Ctns/ mice develop renal dysfunction as soon as
6 months of age and chronic renal failure by the age of 15 months,
and cystine crystals accumulate progressively within interstitial
and proximal tubular cells.17,18 We demonstrated that, in this
context, BMC-derived cells can efficiently get engrafted in
the kidney tissue compartment, lead to a significant decrease
in cystine content, and prevent the progression of kidney
dysfunctions.19 Indeed, 4 months post transplantation, 13%
of the total renal cells as determined by quantitative PCR
(qPCR) were derived from the infused wild-type BMCs
expressing functional Ctns. These BMC-derived cells were
predominately non-lymphoid lineage interstitial cells, but
were also co-localized with distal and proximal tubular,
glomerular, and endothelial cells. Moreover, the treated mice
exhibited normal serum urea and creatinine levels in contrast
to Ctns/ mice treated with Ctns/ BMCs at 4 months post
transplantation. Mesenchymal stem cell transplantation in
this model produced only a short-term improvement in
renal function, perhaps by a paracrine mechanism previously
demonstrated by others,20–22 as there was little evidence of
mesenchymal stem cell engraftment in the kidney.
In the present study, we investigated the long-term effects
of bone marrow-derived stem cell transplantation on the
kidney disease of treated Ctns/ mice up to 15–17 months of
age. We demonstrated that stem cell transplantation could
prevent chronic kidney disease in this model. However,
effective therapy depends on achieving a relatively high level
of Ctns-expressing cells in the bone marrow, which is directly
linked to the number of Ctns-expressing cells found within
the kidney. In contrast, kidney repair was not dependent on
the age of the mice at the time of transplantation; thus,
kidney injury can be improved in animals transplanted after
6 months of age.
RESULTS
We analyzed 30 C57BL/6 Ctns/ mice transplanted for over
7 months with either BMCs (23 mice) or HSCs (7 mice). Of
them, 15 were transplanted between 2 and 6 months of age
and 15 between 6 and 10 months of age. Transplanted cells
were isolated from green fluorescent protein (GFP)-trans-
genic mice. In all, 29 non-treated Ctns/ mice and 27
wild-type mice were used as controls, with both groups age-
matched with the treated mice. Mice were killed between
15 and 17 months of age for a complete analysis, including
cystine levels, kidney Ctns expression, renal function, and
histology. We determined the level of bone marrow engraft-
ment of transplanted cells measured as the percentage of
GFPþ cells in the blood: levels ranged from 0.06 to 93.1%.
The mean of donor-derived cells was 64±29% and the mean
contribution for each lineage was similar for BMCs and
HSC-transplanted cells: 10±5% T-lymphocytes, 21±14%
B-lymphocytes, and 14±8% monocytes. The rest of GFPþ
cells were granulocytes.
Renal function in treated Ctns/ mice depends on blood
engraftment but not on the age of transplantation
Serum creatinine levels were significantly lower in treated
mice compared with Ctns/ control mice, and the baseline
polyuria of the treated Ctns/ mice was improved (Table 1).
However, renal function data showed an important varia-
bility in the treated mice; some mice exhibited normal kidney
function and some had biochemical data similar to non-
treated Ctns/ mice. We demonstrated that the preservation
of the kidneys in the treated mice was directly linked to a
higher level of donor-derived BMC engraftment expressing a
functional Ctns gene. Indeed, linear regression analyses of
renal function data compared with that of blood engraftment
demonstrated that serum creatinine and urea were signifi-
cantly decreased as blood engraftment increased (F1,27¼
7.943, P¼ 0.009, R2¼ 0.227 for creatinine, and F1,27¼
12.656, P¼ 0.001, R2¼ 0.319 for urea; Figure 1a). In these
regression analyses, initial tests for differences between BMC-
and HSC-transplanted mice did not achieve statistical signifi-
cance: F1,26¼ 0.776, P¼ 0.39 for creatinine, and F1,26¼ 1.286,
P¼ 0.27 for urea). We also performed analyses of variance
comparing age-matched wild-type mice, Ctns/ control
mice, and treated Ctns/ mice, with blood engraftment
Table 1 | Serum and urine analyses for renal function
Wild type
(n=27)
Ctns/
(n=29)
Treated
Ctns/ (n=30)
Treated Ctns/ o50%
engraftment (n=9)
Treated Ctns/ 450%
engraftment (n=21)
Serum
Creatinine (mg/dl) 0.25±0.08 0.44±0.19a 0.36±0.15a,b 0.47±0.14a,c 0.31±0.12a,b,d
Creatinine clearance (ml/min) 0.08±0.05 0.06±0.03a 0.05±0.05a 0.03±0.01a,b 0.06±0.06a,d
Urea (mg/dl) 64.36±28.91 103.62±28.19a 108.26±27.92a 130.38±26.06a,b,c 98.31±22.95a,d
Phosphate (mg/dl) 11.78±3.51 12.79±2.18 13.77±3.31a 14.90±5.24a,b 13.26±1.91a
Alkaline phophatase (IU/l) 54.19±25.51 126.92±58.32a 119.87±64.05a 145.62±63.83a 108.27±62.24a
Urine
Phosphate (mmol per 24 h) 2.39±1.59 6.73±5.27a 4.81±4.04a 7.34±5.75a 3.72±2.52a,b
Protein (mg per 24 h) 16.53±15.93 13.84±10.89 10.25±6.80a 7.86±5.61a 11.27±7.12
Volume (ml) 0.61±0.31 1.73±0.92a 1.23±0.85a,b 1.50±0.94a 1.10±0.80a,b
aPo0.05 compared with wild-type mice.
bPo0.05 compared with Ctns/ mice.
cPo0.05 compared with treated Ctns/ mice.
dPo0.05 compared with treated o50% engraftment Ctns/ mice.
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levels inferior and superior to 50% donor engraftment
(Table 1). We found that treated mice with donor-derived cell
engraftment inferior to 50% showed renal function data
similar or worse than non-treated mice. In contrast, treated
mice with engraftment superior to 50% had significantly
improved serum creatinine, urine phosphate, and urine
volumes compared with Ctns/ mice, achieving levels
similar to the wild-type mice (Table 1 and Figure 1b). Serum
urea is also improved compared with Ctns/ mice but the
difference is not significant (Table 1 and Figure 1b). Note that
mice that underwent lethal irradiation and transplantation
are less healthy overall in comparison with the wild-type and
untreated cystinotic animals. This was confirmed by
histological studies showing that transplanted wild-type mice
also presented renal anomalies (see below). Thus, the fact
that our measurements of kidney function in Ctns/ mice,
which have more than 50% of their BMCs expressing
a functional Ctns gene, were consistently improved or
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Figure 1 | Statistical analyses of renal function data. (a) Linear regression analyses of serum creatinine and urea compared with blood
engraftment levels showing a decrease in creatinine and urea measures in mice with a high blood engraftment levels. The linear regression
lines are depicted in red, and the corresponding 95% confidence bands about the lines are depicted in blue. (b) Least squares means and
s.d. as determined from analyses of variance comparing wild-type mice, Ctns/ control mice, and treated Ctns/ mice with blood
engraftment levels inferior and superior to 50% for serum creatinine, urine phosphate, and urine volume. Treated mice with blood
engraftments superior to 50% had significantly improved serum creatinine, urine phosphate, and urine volume compared with Ctns/mice
and similar to wild-type mice. Serum urea is also improved in treated Ctns/ mice with a donor blood engraftment450% compared with
Ctns/ mice but the difference is not significant. (c) Linear regression analyses of serum creatinine and urea compared with age of
transplantation showing no correlation between these parameters.
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even normalized clearly demonstrates the efficacy of this
treatment.
On the other hand, based on analysis of variance, there is
no significant difference in renal function between mice
transplanted before and after 6 months of age (data not
shown). This conclusion was confirmed by a linear regression
analysis of renal function and age of transplant as continuous
variables (F1,27¼ 0.006, P¼ 0.936, R2¼ 0.001 for creatinine,
and F1,27¼ 1.613, P¼ 0.215, R2¼ 0.056 for urea; Figure 1c).
In these regression analyses, initial tests for differences
between BMC- and HSC-transplanted mice did not achieve
statistical significance: F1,26¼ 0.190, P¼ 0.67 for creatinine,
and F1,26¼ 0.078, P¼ 0.78 for urea).
Kidney Ctns expression but not kidney cystine content
depends on blood engraftment in treated Ctns/ mice
To determine the influence of donor-derived cell engraftment
levels on the cystine content and Ctns expression in the
kidney of the treated Ctns/ mice, we measured cystine
content by mass spectrometry and Ctns gene expression by
reverse transcription-qPCR comparing treated mice and
controls. Cystine content was significantly decreased in the
kidneys of treated Ctns/ mice compared with Ctns/
control mice (54% decrease, Table 2). However, linear
regression analyses showed that kidney cystine levels are
independent of the donor-derived cell engraftment levels
(F1,28¼ 3.384, P¼ 0.076). Moreover, renal function data did
not depend on the cystine levels in the kidney (F1,27¼ 0.833,
P¼ 0.370 for creatinine, and F1,27¼ 2.191, P¼ 0.150 for
urea). Cystine levels of treated Ctns/ mice were signifi-
cantly reduced in comparison with Ctns/ controls in all the
other tissues tested; the decrease ranged from 56.5% in the
muscle to 96.5% in the liver (Table 2).
As expected, no Ctns expression was detected in Ctns/
control mice. In parallel, Ctns expression measured by reverse
transcription-qPCR was observed in kidneys from treated
mice (12,225±12,823-fold change) and wild-type mice
(316,209±251,247-fold change). Linear regression analysis
showed that Ctns expression within the kidney significantly
increased with increasing blood engraftment levels (F1,27¼
6.394, P¼ 0.018, R2¼ 0.437). Similarly, an analysis of vari-
ance of Ctns expression in the kidney using the dicho-
tomous variable of greater or less than 50% donor-derived
engraftment levels demonstrated the same positive correla-
tion (11,982±5052 versus 6765±6690; P¼ 0.01).
Histology confirms the biochemical data
The histology of non-treated Ctns/ mice at 15–17 months
of age consistently exhibited severe kidney anomalies
characterized by their multifocal distribution covering a
mean 81% (range 50–95%) of the cortex. The lesions
primarily affected proximal tubules and were characterized
by atrophy to complete disappearance of epithelial cells
and thickening of the tubular basement membranes
(Figure 2a and c). Corresponding medullary tubules were
collapsed and obstructed by protein casts. Within atrophic
areas, glomerular tufts can appear collapsed or sclerotic.
Large and multiple mononuclear infiltrates were present at
the corticomedullary junctions. In contrast, interstitial
fibrosis was not a major finding in the mouse model of
cystinosis, which correlates to that seen in the human.18
Treated Ctns/ mice exhibited similar anomalies but, in
most of the mice with high blood engraftment, their extent
was less extensive than in the non-treated mice (Figure 2b).
Moreover, fewer and smaller lymphoid infiltrates were
observed in the treated mice (Figure 2b and d) than in the
Ctns/ control mice (Figure 2a and c).
We scored the kidney histology from wild-type controls,
Ctns/ and treated mice, with scores ranging from 1 to 6
based on the % extent of cortical damage (see Materials and
Methods). The average score for wild-type mice was 1.1±0.3;
some of the transplanted wild-type mice exhibiting renal
anomalies, such as focal tubular dilatation, presence of a few
medullary casts, or focal glomerulosclerosis, possibly as a
consequence of irradiation and aging (data not shown). The
average score for Ctns/ mice was 5.1±0.9 versus 4.6±1.4
for treated mice. Furthermore, even if the difference was not
significant, the score of treated mice with a donor-derived cell
engraftment level 450% was lower compared with treated
mice with blood engraftment levels o50% (4.1±1.6 versus
5.4±0.7), confirming the renal function data obtained from
biochemical measurements.
Kidney sections stained with methylene blue in ethanol
were used to observe cystine crystals. Low magnification
pictures of kidney sections were taken and analyzed using
ImageJ software (see Materials and Methods). Abundant
Table 2 | Cystine content in multiple tissues of treated and control mice at 15–17 months old
Wild type Ctns/ Treated Ctns/ Percentage decrease in cystinea
Brain 0.02+0.01b 5.09+2.66 1.90+1.24c 62.7
Eye 0.09+0.10 178.91+209.47 33.65+31.71c 81.2
Heart 0.14+0.05 201.27+151.32 79.95+65.10c 60.3
Kidney 0.19+0.05 519.42+564.42 239.09+227.70c 54.0
Liver 0.02+0.01 151.13+55.01 5.23+3.70c 96.5
Muscle 0.24+0.09 58.73+33.04 25.55+23.78c 56.5
Spleen 0.06+0.03 379.06+193.40 27.30+30.98c 92.8
aPercent decrease in cystine content in treated mice compared with Ctns/ mice control.
bCystine content is stated in nmol half-cystine per mg protein.
cPo0.05 compared with non-treated Ctns/ mice.
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cystine crystals were observed in kidney sections from non-
treated Ctns/ mice whereas none or few crystals were
detected in kidney sections from treated mice (683 pixels
±567 versus 57 pixels ±63 respectively, Po0.000001;
Figure 2e and f). Even treated mice with low donor-derived
cell engraftment, and thus very damaged kidneys, exhibited
no or few cystine crystals (Figure 2f).
Characterization of the BM-derived renal interstitial cells
We previously showed that most of the transplanted bone
marrow-derived cells were interstitial in the kidney of treated
Ctns/ mice and few co-localized with proximal tubular
cells.19 In this long-term analysis, we did not observe any
bone marrow-derived epithelial cells but rather abundant
interstitial GFPþ cells in the kidney of treated mice. In the
healthy area of the kidneys, bone marrow-derived cells
appeared elongated and beneath the tubular basement
membrane (Figure 3a). In the areas of focal cortical injury,
we observed that many GFPþ cells were fibroblasts-like cells
expressing ecto-50-nucleotidase (CD73), and others expres-
sing both CD73 and a-smooth muscle actin were myofibro-
blasts (Figure 3b and c). Some cortical GFPþ interstitial cells
were dendritic cells stained by both MHC class II and CD11c
(Figure 3d). However, they were mostly part of the
Figure 2 |Histological analyses of kidney sections. Kidney
anomalies observed in treated and non-treated Ctns/ mice.
Histological pictures of kidney sections stained with hematoxylin
and eosin (a–d) and methylene blue (e, f). (a, c) Ctns/ mice
controls exhibit severe kidney anomalies characterized by their
multifocal distribution. Proximal tubules were atrophic or
completely disappeared, and less frequently tubules were dilated.
Glomerular tufts were normal, collapsed, or sclerotic. Large
and multiple mononuclear infiltrates were present at the
corticomedullary junction. (b) Treated Ctns/ mice with high
blood engraftment exhibited the same histological anomalies but
to a much lesser extent than in the non-treated mice. (d) Fewer
lymphoid infiltrates were observed in the treated mice even with
important histological anomalies. (e) Abundant cystine crystals
are observed in non-treated Ctns/ mice. (f) Very few cystine
crystals are observed in treated Ctns/ mice even with a
damaged kidney.
Figure 3 |Characterization of bone marrow-derived green
fluorescent protein (GFP)þ cells within the kidney of
15–17-month-old Ctns/ mice. Representative Z-series confocal
microscopy pictures of treated Ctns/ mice’s kidney sections.
Transplanted, bone marrow-derived GFPþ cells are seen in green.
(a) Proximal tubular staining by Lotus Tetragonolobus lectin (red).
GFPþ cells are interstitial and appear elongated around the tubes.
(b) Renal cortical fibroblasts expressing CD73 are seen in blue and
MHC class II expressing interstitial cells are seen in red. Some
GFPþ cells express either CD73 (*) or MHC class II-labeled cells (^).
(c) Some GFPþ cells express both a smooth muscle actin (red)
and CD73 (blue) and thus are myofibroblasts (arrows). (d) Some
GFPþ cells are dendritic cells (arrows) stained with both MHC
class II (blue) and CD11c (red). (e) No colocalization was observed
between GFPþ cells and conventional dendritic cells stained by
both CD11c (red) and CD103 (blue). (f) Some GFPþ cells belong to
the inflammatory dendritic cell subset (arrows) stained with both
CD11c (red) and F4/80 (blue). Bars¼ 10mm (a, b), 15mm (c, e), and
20mm (d, f).
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inflammatory dendritic cell subset (CD11cþ and F4/80þ ;
Figure 3f), as opposed to conventional dendritic cells
(CD11cþ and CD103þ ; Figure 3e). Finally, we noticed that
bone marrow-derived GFPþ cells expressing CD45, a pan-
leukocyte marker, were present in juxtamedullary infiltrates
as well as in atrophic scars (data not shown). In the kidney
of transplanted wild-type mice, very few GFPþ cells were
observed even after a year post transplantation (data not
shown), which confirmed our previous findings that bone
marrow-derived cell integration within the kidney occurred
specifically in injured kidney.19
DISCUSSION
We previously showed that transplantation of BMCs and
HSCs expressing a functional Ctns gene led to a significant
cystine decrease in all tissues as well as the preservation of
kidney function at 4 months post transplantation in the
mouse model for cystinosis.19 The present study represents
the long-term follow-up of treated mice, age of 15–17
months. Three important conclusions can now be drawn
from this new work: (1) transplantation of bone marrow
stem cells expressing a functional Ctns gene significantly
decreases long-term cystine accumulation in all tested tissues
including kidneys (from 56.5% decrease in the muscle to
96.5% in the liver), (2) transplantation of bone marrow stem
cells expressing a functional Ctns gene can provide long-term
protection to the kidney, and (3) there is a threshold for the
level of donor-derived blood cell engraftment necessary for
preservation of kidney histology and function, and this
correlates with increased expression of the Ctns gene in the
kidney.
These results suggesting correlations between therapeutic
success in the kidney and levels of transplanted cell
engraftment may provide new insights into the controversial
field of using adult bone marrow stem cells for kidney repair.
We propose that differences in the levels of engraftment may
explain some of the discrepancies and non-reproducibility
of previously reported results. Some authors showed that
BMCs could migrate to damaged kidneys and reverse renal
dysfunction.7–11 By contrast, other studies showed that BMCs
could not generate renal cells or impact kidney injury.12–16 In
our mouse model of cystinosis, the data presented demon-
strate that, in the context of chronic and progressive renal
damage, bone marrow-derived cells can efficiently engraft in
the kidney, generate interstitial renal cells, and decrease
progression of kidney dysfunction if the level of Ctns-
expressing cells engrafted in the bone marrow is sufficient.
These data could also explain the lack of improvement of
acute tubular damage by transplanted BMCs in non-
irradiated mice.23 Even if transplanted cells were engrafted
in the bone marrow, the level of donor cell engrafted was
probably too low (B30%).
Moreover, the kinetics and/or the mechanism of cell death
in the kidney might be important to generate the necessary
stimuli driving stem cell mobilization, migration, and
integration in the kidney. We showed previously and
confirmed here that, in contrast to the treated Ctns/ mice,
few bone marrow-derived cells are engrafted in the kidneys of
wild-type mice transplanted with the syngeneic GFPþ cells.
These results support the conclusion that renal injury is a
necessary factor. However, the extent and chronicity of
the cystinosis injury is also important. This hypothesis is
supported by studies in a mouse model of Hepatorenal
Tyrosinemia, Type 1 (HT1). HT1 is characterized by the
accumulation of fumarylacetoacetate due to the lack of
fumarylacetoacetate hydrolase (FAH) expressed in liver and
proximal tubular cells.24 Affected patients develop both liver
injury and renal Fanconi syndrome.25 The mouse model is
neonatal lethal, but animals can survive if treated with
cyclohexanedione.26 However, renal tubule repopulation by
Fahþ bone marrow stem cells did not occur presumably
because of the mild renal disease in these treated mice.27
Similarly, no renal tubule repopulation was observed after
induction of acute tubular necrosis. Therefore, the investi-
gators modified the HT1 model to induce chronic renal
injury by backcrossing the Fah/ mice to the homogentisic
acid dioxygenase-deficient mice, an enzyme upstream of Fah
in the pathway, leading to the accumulation of the toxic
fumarylacetoacetate substrate in the proximal tubules. As a
consequence, there was a dramatic increase in the repopula-
tion of renal tubules (up to 50%) and correction of the
kidney dysfunction. Thus, we propose that another reason for
discrepancies in different models might be differences in the
extent and chronicity of the renal injury particularly as many
of the studied models represent dramatic acute injury.
Surprisingly, we did not observe any correlation between
renal function and cystine content, indicating that kidney
damage is not directly linked to cystine levels in this
compartment. This is further supported by the fact that
none or few cystine crystals were observed in kidney sections
from treated Ctns/ mice, even in the animals with low
blood engraftment levels and extensive kidney damage. Thus,
these new results show that bone marrow-derived cells
specifically lead to the correction of the cells containing
cystine crystals, which are probably apoptotic.28,29 They also
demonstrate that the accumulation of tissue cystine in the
kidney is not the only cause of the tissue injury in cystinosis.
This is relevant to the pathophysiology of the cystinosis
nephropathy in human patients, which remains incompletely
understood.29–33 Thus, proximal tubulopathy is typically
found as early as 6 months of age whereas the multi-
compartment tissue injuries correlated with increased onset
of cystine crystals occur after 10 years of age.34
Bone marrow-derived cells are localized mostly in the
interstitium within the kidneys of Ctns/ mice transplanted
with BMCs or HSCs expressing a functional Ctns gene. These
cells differentiated into lymphoid, dendritic, or fibroblastic/
myofibroblastic cells. We showed by confocal microscopy that
the majority of the bone marrow-derived (for example,
GFPþ ) dendritic cells are inflammatory type dendritic cells
that we propose are involved in kidney repair by inhibiting
the inflammatory response, as suggested by others.35 In this
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context, we showed that fewer and smaller mononuclear
cell infiltrates were consistently observed in the treated mice
than in the Ctns/ mice controls. Moreover, as we are not
demonstrating that the bone marrow-derived cells are simply
replacing the kidney epithelium, the obvious question is how
do these interstitial cells protect the cystinotic kidneys. BMCs
could indirectly affect tubule regeneration or preservation as
suggested previously.13 One possibility could be the inter-
cellular transfer of the cystinosin protein or mRNA from
the bone marrow-derived interstitial cells to the epithelium.
A second possibility is that these interstitial cells provide
some kind of survival factors protecting the nearby epithelial
cells from injury. In the context of acutely injured kidney,
Fujigaki et al.36 showed that fibroblastic cells develop
increased number of cytoplasm-containing microfilament
bundles extending into the tubular basement membranes and
in parallel differentiate into myofibroblasts.
Finally, we showed that there is no significant difference in
the preservation of renal function between mice transplanted
before and after 6 months of age, suggesting that if the renal
anomalies are not too advanced, BMC transplantation in
older animals can still contribute to the preservation of the
kidney. This is important for cystinotic patients as they now
live longer with oral cysteamine therapy and eventually
develop chronic kidney disease. Thus, we propose that bone
marrow transplantation, even in young adults, could still
allow the survival of their kidneys. However, our results
suggest that there is a necessary engraftment threshold such
that the quantity of cells expressing Ctns gene in the bone
marrow will determine the success of this therapy. We also
showed that HSC transplantation modeled in mice by puri-
fication of Sca1þ HSCs has the same therapeutic effects as
whole BMC transplantation in the mouse model of cystinosis.
This has a significant implication for the clinical translation
of these data to patients, as human HSCs (CD34þ ) have the
advantages to be easily isolated from the peripheral blood
after growth factor-mediated mobilization (that is, granulo-
cyte macrophage colony-stimulating factor). All these data
will have to be carefully considered in the design of any future
clinical trial using adult bone marrow stem cells for cystinosis
and possibly for other hereditary nephropathies.
MATERIALS AND METHODS
Mice
C57BL/6 Ctns/ mice were provided by Dr C. Antignac
(Inserm U983, Paris, France) and bred continuously at The
Scripps Research Institute. Transgenic mice constitutively
expressing GFP (C57BL/6-Tg(ACTB-EGFP)1Osb/J) were
obtained from The Jackson Laboratory, Bar Harbor, MI. All
protocols were approved by the AAALAC (Accredited
Institutional Animal Care and Use Committee of The Scripps
Research Institute).
BMC and HSC isolation and cell transplantation
BMCs were flushed from the long bones of 6–8-week-old GFP
mice and transplanted without further culture or processing.
Sca1þ HSCs were sorted using anti-Sca1 antibody conju-
gated to mini-magnetic beads (Miltenyi Biotec, Auburn, CA).
Cells were injected via the tail vein in 2–10-month-old mice.
All mice were lethally irradiated (cesium radiation, 8 Gy) on
the day preceding the injection. To analyze engraftment,
fresh blood was treated with red blood cell lysis buffer
(eBioscience, San Diego, CA) and subsequently analyzed
by flow cytometry to quantify GFPþ cells. Lineage-specific
staining and flow cytometry allowed determination of the
hematopoietic chimerism for T cells (Cy-chrome-conjugated
anti-CD3e; BD Biosciences Pharmingen, San Jose, CA), B
cells (phycoerythrin-conjugated anti-CD19; BioLegend,
San Diego, CA), and macrophages (phycoerythrin-conju-
gated MAC3; BD Biosciences Pharmingen). Appropriate
isotype controls were used for each. Mice were killed between
15 and 17 months of age.
Blood and urine analysis
Serum was obtained by cardiac puncture, and 24 h urine
samples were collected in metabolic cages before killing the
mice. Serum and urine phosphate levels as well as serum
creatinine, urea, and alkaline phosphatase were estimated by
using colorimetric assays according to the manufacturer’s
recommendations (BioAssay Systems, Hayward, CA). Protein
levels in urine were measured using Pierce BCA Protein Assay
Kit (Rockford, IL).
Cystine content measurement
Explanted tissues were grounded in 500 ml of N-ethylmalei-
mide (Fluka Biochemika, Bushs, Switzerland) at 650 mg/ml
for cystine measurements. The proteins were precipitated
using 15% 5-sulfosalicylic acid dihydrate (Fluka Biochemika),
resuspended in 0.1 N NaOH and measured using the Pierce BCA
protein assay kit. The cystine-containing supernatants were sent
to the UCSD Biochemical Genetics laboratory (San Diego, CA)
for measurements by stable isotope dilution high performance
liquid chromatography-electrospray ionization tandem mass
spectrometry using a Teicoplanin (CHIROBIOTIC T, Sigma,
St Louis, MO) column and specific transitions (MRM).
Quantitative reverse transcription-PCR
RNA was isolated from explanted kidneys by homogenization
in 750 ml Trizol LS Reagent (Invitrogen). Phase separation
was performed with the addition of 200 ml chloroform follo-
wed by centrifugation. After removal of the aqueous phase,
RNA was recovered by precipitating with isopropyl alcohol.
RNA was purified using the RNeasy mini-protocol for RNA
cleanup, including column DNase treatment (Qiagen,
Valencia, CA). A total of 1 mg of RNA for each tissue was
reverse transcribed using iScript cDNA Synthesis Kit
(Bio-Rad, Hercules, CA). Ctns-specific qPCR was performed
using 2ml of cDNA and 2 Universal TAQ man master
mix (Roche Diagnostics, Indianapolis, IN), Ctns primer mix
(in Ctns exon 8: Ctns oligo 1: 50-TTGTGGCTGCAGTC
GGTATC-30, Ctns oligo 2: 50-AGCTTGATGTAGGAGAAGCA
GAAGA-30, and Ctns probe: 50-CACATGGCTCCAGTTC-30
1204 Kidney International (2011) 79, 1198–1206
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(Applied Biosystems, Foster City, CA)), and 18S primer mix
(Applied Biosystems) on an Applied Biosystems 7900 HT.
The expression level of Ctns gene, expressed as fold change,
was calculated using the DDCt method between the target
gene and an endogenous control (18S).
Histology
Kidneys were fixed in formalin and embedded in paraffin.
Sections were stained with hematoxylin and eosin or briefly
stained with methylene blue in absolute alcohol for the
detection of cystine crystals. Slides were reviewed in a blinded
fashion by one of us (Dr MC Gubler). In cystinotic mice,
kidney lesions develop focally in the cortex and between focal
scars the renal parenchyma is preserved. Blinded scoring was
done from 1 to 6 based on the extent of cortical damage
estimated in % terms: 1 (0–10% damaged kidney),
2 (10–30%), 3 (30–50%), 4 (50–70%), 5 (70–90%), and
6 (490%). Cystine crystals were quantified using ImageJ
software on low magnification pictures of methylene blue-
stained sections covering most of the kidney section for each
mouse. The threshold was adjusted to recognize specifically
the cystine crystals, and pixels were quantified.
Immunofluorescence analysis
Kidneys were fixed in 5% formaldehyde for 30 min,
equilibrated in 20% sucrose overnight and frozen in Tissue-
Tek Optimal Cutting Temperature buffer at 801C (Sakura
Finetek USA, Torrance, CA). Sections of 12 mm were blocked
with 1% bovine serum albumin, 10% donkey or goat serum
in phosphate buffer saline. The blocking buffer was then
diluted 1:5 in phosphate buffer saline and used to dilute the
antibodies as denoted below, all secondary antibodies were
diluted 1:100 and incubated with the sections for 1 h at room
temperature. We used the directly labeled Alexa 647-conjugated
anti-F4/80 (1:25 dilution) and Alexa Fluor 647 phalloidin
(1:500 dilution, Molecular Probes, Eugene, OR). We also
used the biotinylated-conjugated Lotus Tetragonolobus lectin
(1:100 dilution, Vector Laboratories, Burlingame, CA), anti-
mouse CD45 (1:200 dilution), and anti-mouse I-A/I-E MHC
class II (1:200 dilution, BD Pharmingen), followed by strepta-
vidin Alexa 594 (Molecular Probes). Kidney sections were
also stained with the rat anti-mouse CD73 (1:200 dilution)
and CD103 (1:100 dilution; BD Pharmigen), followed by goat
anti-rat conjugated with Cy5 (Jackson ImmunoResearch, West
Grove, PA). Finally, we used the monoclonal anti-a-smooth
muscle actin (clone 1A4, 1:200 dilution; Sigma) followed by
goat anti-mouse conjugated with Texas Red (Jackson Immuno-
Research), and the hamster anti-mouse CD11c antibody (1:50
dilution, BD Pharmingen) followed by goat anti-hamster
conjugated with DyLight 594 (Jackson ImmunoResearch).
All slides were counterstained with 4,6-diamidino-2-phenyl-
indole (1:500 dilution in phosphate buffer saline for 30 min,
Molecular Probes). Images were acquired using a Zeiss
LSM 710 laser scanning confocal microscope attached to a
Zeiss Observer Z1 inverted microscope (BioRad-Carl Zeiss,
Thornwood, NY). All images were 8-bit optical image
slices (0.5 mm interval step slices) acquired using Zen 2009
software (Carl Zeiss MicroImaging GmbH, Thornwood, NY).
Images were then analyzed with IMARIS 6.5 imaging software
(Bitplane Scientific Solutions, Saint Paul, MN) to generate
3-D reconstruction series of optical slices (Z-stacks).
Statistics
We summarized continuous data as arithmetic means±s.d.
Group comparisons of renal function parameters were made
with parametric analyses of variance, followed by Tukey’s
HSD (Honestly Significant Difference) procedure for pair-
wise comparisons. Associations between blood engraftment
and renal function were investigated with linear regressions.
All analyses were performed in Systat 12 (Systat Software,
Chicago, IL, 2007). Po0.05 was considered as statistically
significant. Differences in histology scores across the different
groups were compared with the Kruskal–Wallis test, followed
by Dunn’s multiple comparison procedure.
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